Cost‐effectiveness of sodium‐glucose cotransporter‐2 inhibitors in the treatment of diabetic nephropathy in Japan

Documenti analoghi

• Renal outcomes with sodium‐glucose cotransporter 2 inhibitors in Japanese people with grade 3 chronic kidney disease and type 2 diabetes: Analysis of medical administrative databases
  di: Hiroaki Iijima, et al.
  Pubblicazione: (2024)
• Real‐world effectiveness of sodium‐glucose cotransporter‐2 inhibitors on the progression of chronic kidney disease in patients without diabetes, with and without albuminuria
  di: Afif Nakhleh, et al.
  Pubblicazione: (2024)
• Risk of insulin initiation with sodium‐glucose cotransporter‐2 inhibitors versus dipeptidyl peptidase‐4 inhibitors in patients with type 2 diabetes mellitus: A real‐world claims database study in Japan
  di: Ryo Suzuki, et al.
  Pubblicazione: (2025)
• Use of sodium‐glucose cotransporter‐2 inhibitors in France: Analysis of French nationwide health insurance database
  di: Sibylle de Germay, et al.
  Pubblicazione: (2024)
• Association of initial serum sodium change and clinical outcome in patients with diabetes receiving sodium–glucose cotransporter‐2 inhibitor therapy: A multicentre database analysis in Taiwan
  di: Yu‐Wen Cheng, et al.
  Pubblicazione: (2024)